<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="7759">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00891657</url>
  </required_header>
  <id_info>
    <org_study_id>GYN-08-002</org_study_id>
    <nct_id>NCT00891657</nct_id>
  </id_info>
  <brief_title>Post Market Study for an Adhesion Barrier Following Laparoscopic Myomectomy</brief_title>
  <official_title>A Randomised, Prospective, Multi-Centre Clinical Study of SprayShield™ Adhesion Barrier System as a Barrier for the Prevention of Adhesion Formation After Laparoscopic Myomectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Integra LifeSciences Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Integra LifeSciences Corporation</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is planned as a prospective, randomised, parallel, controlled, multi-centre, open
      label, comparative evaluation of SprayShield™ Adhesion Barrier plus good surgical technique,
      versus good surgical technique alone, with a blinded, third party video evaluation of
      adhesion formation at second look laparoscopy (SLL) following laparoscopic myomectomy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Number of Sites Adherent to the Uterus</measure>
    <time_frame>8-12 weeks post myomectomy</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The number of times an adhesion is attached to the uterus.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Severity Score of Sites Adherent to the Uterus</measure>
    <time_frame>8-12 weeks post myomectomy</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The scoring for severity is as follows: 0=no adhesions, 1=filmy, avascular adhesions, 2=vascular and/or dense adhesions, and 3=cohesive adhesions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Extent Score of Sites Adherent to the Uterus</measure>
    <time_frame>8-12 weeks post myomectomy</time_frame>
    <safety_issue>No</safety_issue>
    <description>0 =no adhesions, 1=covering &lt;25% of locations' total area, 2=covering 26% to 50% of locations' total area, and 3=covering &gt;51% of locations' total area.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area of Sites Adherent to the Uterus (cm^2)</measure>
    <time_frame>8-12 weeks post myomectomy</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Fibroid</condition>
  <condition>Myoma</condition>
  <condition>Leiomyoma</condition>
  <arm_group>
    <arm_group_label>SprayShield™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SprayShield™</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No adhesion barrier administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SprayShield™</intervention_name>
    <description>Anti-adhesion barrier</description>
    <arm_group_label>SprayShield™</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females, 18 years of age or older, of child-bearing potential.

          -  Subject has at least one myoma &gt;= 3 cm.

        Exclusion Criteria:

          -  Pregnant or lactating females.

          -  Females undergoing prior open or closed myomectomy for treatment of myomas.

          -  Evidence of current active endometriosis or infection

          -  History of or active inflammatory bowel disease or pelvic inflammatory disease.

          -  Presence of a frozen pelvis, or hydrosalpinges.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rudy Leon De Wilde, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pius Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pius Clinic</name>
      <address>
        <city>Oldenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <lastchanged_date>September 4, 2014</lastchanged_date>
  <firstreceived_date>April 30, 2009</firstreceived_date>
  <firstreceived_results_date>July 13, 2010</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adhesion</keyword>
  <keyword>Fibroid</keyword>
  <keyword>Myoma</keyword>
  <keyword>Leiomyoma</keyword>
  <keyword>Myomectomy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leiomyoma</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between November 10, 2008 and March 4, 2009, a total of 15 subjects were consented for potential participation, of whom all 15 subjects were randomized. There were no intra-operative screen failures.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>SprayShield™</title>
          <description>The SprayShield™ is a synthetic, sprayable polyethylene glycol (PEG) based absorbable gel adhesion barrier, that consists of two liquids that when mixed together rapidly cross-link to form a biocompatible absorbable flexible hydrogel that conforms and adheres to the tissues to which it is applied.</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>The subjects randomized to the Control group received standard good surgical care, excluding any use of anti-adhesion products.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>SprayShield™</title>
          <description>The SprayShield™ is a synthetic, sprayable polyethylene glycol (PEG) based absorbable gel adhesion barrier, that consists of two liquids that when mixed together rapidly cross-link to form a biocompatible absorbable flexible hydrogel that conforms and adheres to the tissues to which it is applied.</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>The subjects randomized to the Control group received standard good surgical care, excluding any use of anti-adhesion products.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="15"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="15"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="35.8" spread="4.6"/>
                <measurement group_id="B2" value="44.3" spread="3.3"/>
                <measurement group_id="B3" value="39.2" spread="5.9"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="15"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Germany</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="15"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Sites Adherent to the Uterus</title>
        <description>The number of times an adhesion is attached to the uterus.</description>
        <time_frame>8-12 weeks post myomectomy</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Number of subjects to have had a second laparoscopic look.</population>
        <group_list>
          <group group_id="O1">
            <title>SprayShield™</title>
            <description>The SprayShield™ is a synthetic, sprayable polyethylene glycol (PEG) based absorbable gel adhesion barrier, that consists of two liquids that when mixed together rapidly cross-link to form a biocompatible absorbable flexible hydrogel that conforms and adheres to the tissues to which it is applied.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>The subjects randomized to the Control group received standard good surgical care, excluding any use of anti-adhesion products.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Sites Adherent to the Uterus</title>
            <description>The number of times an adhesion is attached to the uterus.</description>
            <units>Adhesion Sites</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.1" spread="1.0"/>
                  <measurement group_id="O2" value="0.6" spread="0.9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Severity Score of Sites Adherent to the Uterus</title>
        <description>The scoring for severity is as follows: 0=no adhesions, 1=filmy, avascular adhesions, 2=vascular and/or dense adhesions, and 3=cohesive adhesions.</description>
        <time_frame>8-12 weeks post myomectomy</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Number of subjects to have had a second laparoscopic look.</population>
        <group_list>
          <group group_id="O1">
            <title>SprayShield™</title>
            <description>The SprayShield™ is a synthetic, sprayable polyethylene glycol (PEG) based absorbable gel adhesion barrier, that consists of two liquids that when mixed together rapidly cross-link to form a biocompatible absorbable flexible hydrogel that conforms and adheres to the tissues to which it is applied.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>The subjects randomized to the Control group received standard good surgical care, excluding any use of anti-adhesion products.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Severity Score of Sites Adherent to the Uterus</title>
            <description>The scoring for severity is as follows: 0=no adhesions, 1=filmy, avascular adhesions, 2=vascular and/or dense adhesions, and 3=cohesive adhesions.</description>
            <units>Scores on a Scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.63" spread="1.06"/>
                  <measurement group_id="O2" value="0.8" spread="1.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Extent Score of Sites Adherent to the Uterus</title>
        <description>0 =no adhesions, 1=covering &lt;25% of locations’ total area, 2=covering 26% to 50% of locations’ total area, and 3=covering &gt;51% of locations’ total area.</description>
        <time_frame>8-12 weeks post myomectomy</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>SprayShield™</title>
            <description>The SprayShield™ is a synthetic, sprayable polyethylene glycol (PEG) based absorbable gel adhesion barrier, that consists of two liquids that when mixed together rapidly cross-link to form a biocompatible absorbable flexible hydrogel that conforms and adheres to the tissues to which it is applied.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>The subjects randomized to the Control group received standard good surgical care, excluding any use of anti-adhesion products.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Extent Score of Sites Adherent to the Uterus</title>
            <description>0 =no adhesions, 1=covering &lt;25% of locations’ total area, 2=covering 26% to 50% of locations’ total area, and 3=covering &gt;51% of locations’ total area.</description>
            <units>Scores on a Scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.92" spread="0.66"/>
                  <measurement group_id="O2" value="0.6" spread="0.89"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area of Sites Adherent to the Uterus (cm^2)</title>
        <time_frame>8-12 weeks post myomectomy</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>SprayShield™</title>
            <description>The SprayShield™ is a synthetic, sprayable polyethylene glycol (PEG) based absorbable gel adhesion barrier, that consists of two liquids that when mixed together rapidly cross-link to form a biocompatible absorbable flexible hydrogel that conforms and adheres to the tissues to which it is applied.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>The subjects randomized to the Control group received standard good surgical care, excluding any use of anti-adhesion products.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Area of Sites Adherent to the Uterus (cm^2)</title>
            <units>cm^2</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2.19" spread="2.32"/>
                  <measurement group_id="O2" value="2.7" spread="5.24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>10 November 2008 (first subject consented) to 09 May 2009 (last subject follow-up visit date)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>SprayShield™</title>
          <description>The SprayShield™ is a synthetic, sprayable polyethylene glycol (PEG) based absorbable gel adhesion barrier, that consists of two liquids that when mixed together rapidly cross-link to form a biocompatible absorbable flexible hydrogel that conforms and adheres to the tissues to which it is applied.</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>The subjects randomized to the Control group received standard good surgical care, excluding any use of anti-adhesion products.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The very small sample size makes it difficult to detect any real differences between the treatments, if such differences exist.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Global Director, Clinical Affairs - BioSurgery</name_or_title>
      <organization>Confluent Surgical</organization>
      <phone>781.839.1770</phone>
      <email>jennifer.doyle@covidien.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
